Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Mitsubishi Tanabe Sees Bullish Simponi, but Sales Slightly Lower on Price Revision
Mitsubishi Tanabe Pharma said on May 10 that its revenue edged down in FY2016 compared to the previous year as strong sales of its rheumatoid arthritis (RA) drug Simponi (golimumab) and other priority products failed to cover the negative impact…
To read the full story
Related Article
- Mitsubishi Tanabe Logs Record Sales, but Profits Sag on Higher R&D/SGA Costs
May 10, 2018
- Mitsubishi Tanabe’s Half-Year Sales Up 4.5%, but Profits Dip on Radicava Promotion Costs
November 2, 2017
- Mitsubishi Tanabe Eyes M&As for Post-Radicava Strategy in US: President
May 11, 2017
- Mitsubishi Tanabe Ekes Out Sales Rise on Simponi, Other Major Products
November 2, 2016
- Mitsubishi Tanabe’s Sales Rise on Royalty, Upfront Revenues
May 12, 2016
BUSINESS
- Astellas Expands AI Drug Discovery to TPDs, Engineered Proteins
July 30, 2026
- Regeneron Japan Files First Dual-AAV Therapy for Genetic Hearing Loss
July 30, 2026
- Shionogi’s Xocova Debuts in US for COVID-19 PEP
July 30, 2026
- Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
- Leqembi Global Sales Rise to 29.3 Billion Yen in April-June: Eisai
July 30, 2026
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…